NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 08 04:00PM ET
7.85
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-0.88 Insider Own20.70% Shs Outstand65.50M Perf Week0.00%
Market Cap520.01M Forward P/E- EPS next Y-1.47 Insider Trans-1.27% Shs Float52.53M Perf Month390.62%
Income-46.36M PEG- EPS next Q-0.28 Inst Own67.83% Short Float4.02% Perf Quarter518.11%
Sales0.00M P/S- EPS this Y-43.09% Inst Trans-1.03% Short Ratio1.15 Perf Half Y426.85%
Book/sh1.17 P/B6.73 EPS next Y-25.28% ROA-80.67% Short Interest2.11M Perf Year223.05%
Cash/sh1.14 P/C6.86 EPS next 5Y-9.32% ROE-95.00% 52W Range0.83 - 8.20 Perf YTD396.84%
Dividend Est.- P/FCF- EPS past 5Y40.21% ROI-60.45% 52W High-4.27% Beta0.40
Dividend TTM- Quick Ratio10.52 Sales past 5Y-10.71% Gross Margin- 52W Low845.67% ATR (14)0.41
Dividend Ex-Date- Current Ratio10.52 EPS Y/Y TTM44.85% Oper. Margin- RSI (14)92.31 Volatility0.87% 8.65%
Employees34 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom2.67 Target Price8.80
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q51.00% Payout- Rel Volume0.38 Prev Close7.85
Sales Surprise- EPS Surprise38.78% Sales Q/Q- EarningsMay 08 AMC Avg Volume1.84M Price7.85
SMA2083.15% SMA50202.00% SMA200342.11% Trades Volume696,064 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-27-25Upgrade Wells Fargo Equal Weight → Overweight $3 → $6
Aug-02-24Initiated Oppenheimer Outperform $7
Mar-18-24Initiated Leerink Partners Outperform $6
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
May-08-25 04:49PM
04:05PM
May-02-25 09:39AM
May-01-25 12:15PM
07:26AM
04:30PM Loading…
Apr-30-25 04:30PM
08:15AM
07:50AM
07:24AM
07:00AM
Apr-24-25 09:55AM
Apr-18-25 03:25PM
Apr-02-25 08:00AM
Mar-28-25 09:00AM
Mar-27-25 07:00AM
12:00PM Loading…
Mar-19-25 12:00PM
Mar-18-25 04:44AM
Mar-13-25 04:18PM
04:05PM
Mar-04-25 08:00AM
Feb-21-25 03:42AM
Feb-04-25 08:00AM
Jan-29-25 12:48PM
07:00AM
Nov-26-24 08:00AM
Nov-07-24 05:13PM
04:05PM
Oct-29-24 06:01AM
Oct-08-24 08:00AM
Aug-28-24 08:00AM
05:19PM Loading…
Aug-08-24 05:19PM
04:05PM
Aug-06-24 08:00AM
Jul-09-24 08:00AM
Jun-24-24 07:00AM
Jun-04-24 08:00AM
May-16-24 08:00AM
May-09-24 10:57PM
05:16PM
04:05PM
May-07-24 06:00AM
May-06-24 08:00AM
Apr-30-24 08:00AM
Mar-23-24 05:33AM
Mar-21-24 10:53PM
04:22PM
04:05PM
Mar-13-24 12:09PM
Mar-12-24 06:32AM
06:30AM
Jan-02-24 04:05PM
Nov-22-23 08:00AM
Nov-09-23 04:32PM
04:05PM
Nov-02-23 08:00AM
Oct-19-23 08:00AM
Sep-20-23 07:00AM
Sep-13-23 08:00AM
Sep-05-23 08:00AM
Aug-24-23 07:33PM
Aug-23-23 01:04PM
08:00AM
Aug-08-23 04:43PM
04:05PM
Aug-02-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-23-23 08:00AM
Jun-20-23 08:00AM
Jun-12-23 08:00AM
May-16-23 08:00AM
May-11-23 04:18PM
04:05PM
Apr-13-23 08:00AM
Apr-12-23 04:05PM
Mar-23-23 04:52PM
04:05PM
Feb-09-23 08:00AM
Jan-13-23 04:05PM
Jan-09-23 06:01AM
Dec-12-22 08:00AM
Nov-29-22 05:43PM
08:00AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 08:00AM
Sep-13-22 11:58AM
Sep-12-22 11:14AM
08:00AM
Sep-02-22 04:05PM
Aug-11-22 04:10PM
Aug-04-22 08:00AM
Jun-21-22 08:00AM
Jun-13-22 08:00AM
Jun-02-22 08:00AM
May-17-22 04:30PM
07:00AM
May-12-22 04:05PM
10:20AM
May-11-22 08:00AM
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PChief Executive OfficerJan 30 '25Buy1.0950,00054,260260,808Jan 31 05:00 PM
BALTIMORE DAVIDDirectorJan 30 '25Buy1.0619,61020,78722,169Jan 31 05:00 PM
Aker Christopher RaySr. VP & General CounselJan 13 '25Sale1.2638,54748,69354,634Jan 15 05:00 PM
Aker Christopher RaySr. VP & General CounselJan 14 '25Sale1.265,0886,42749,546Jan 15 05:00 PM
Hagan Joseph PChief Executive OfficerJan 13 '25Sale1.26115,290145,634222,572Jan 15 05:00 PM
Hagan Joseph PChief Executive OfficerJan 14 '25Sale1.2611,76414,860210,808Jan 15 05:00 PM
CALSADA CRISPINAChief Financial OfficerJan 13 '25Sale1.2638,71648,90650,566Jan 15 05:00 PM
CALSADA CRISPINAChief Financial OfficerJan 14 '25Sale1.265,0886,42745,478Jan 15 05:00 PM
Klassen PrestonPresident & Head of R & DJan 13 '25Sale1.2631,44539,72136,055Jan 15 05:00 PM
Collier Kathryn JDirectorJul 25 '24Buy1.824,0007,2806,740Jul 29 04:18 PM